TY - JOUR T1 - Pregnancy Outcome in Juvenile Systemic Lupus Erythematosus: A Brazilian Multicenter Cohort Study JF - The Journal of Rheumatology JO - J Rheumatol SP - 1414 LP - 1418 VL - 35 IS - 7 AU - CLOVIS A.A. SILVA AU - MARIA O. HILARIO AU - MARILIA V. FEBRONIO AU - SHEILA K. OLIVEIRA AU - ROZANA G. ALMEIDA AU - ADRIANA R. FONSECA AU - EDSON M. YAMASHITA AU - MARCOS V. RONCHEZEL AU - LUCIENE L. CAMPOS AU - SIMONE APPENZELLER AU - MARIA V. QUINTERO AU - ANA B. SANTOS AU - ANA C. MEDEIROS AU - LUCIANA M. CARVALHO AU - TERESA C. ROBAZZI AU - SILVANA P. CARDIN AU - ELOISA BONFA Y1 - 2008/07/01 UR - http://www.jrheum.org/content/35/7/1414.abstract N2 - Objective To determine pregnancy outcome and fetal loss risk factors in patients with juvenile systemic lupus erythematosus (JSLE). Methods A total of 315 female patients with JSLE followed in 12 Brazilian pediatric rheumatology centers were consecutively selected. Menarche was observed in 298 (94.6%) patients. Patients’ medical records were reviewed for pregnancy outcomes and demographic, clinical, and therapeutic data. Results A total of 24 unplanned pregnancies occurred in 298 (8%) patients. The outcomes were 5 (21%) early fetal losses (prior to 16 wks gestation), 18 (75%) live births, and 1 (4%) death due to preeclampsia and premature birth. The frequencies of active diffuse proliferative glomerulonephritis, proteinuria ≥ 0.5 g/day, and arterial hypertension at the beginning of pregnancy were higher in pregnancies resulting in fetal losses than in live births [60% vs 5% (p = 0.02), 60% vs 5% (p = 0.02), 60% vs 5% (p = 0.02), respectively]. JSLE pregnancies with fetal losses had a significantly higher mean SLE Disease Activity Index 2000 (SLEDAI-2K) at the start of pregnancy compared with those with live births (9.40 ± 7.47 vs 3.94 ± 6.00; p = 0.049). Four pregnancies were inadvertently exposed to intravenous cyclophosphamide therapy for renal involvement despite contraceptive prescriptions, resulting in fetal loss in 3 (p = 0.02). In multivariate analysis only intravenous cyclophosphamide use at start of pregnancy (OR 25.50, 95% CI 1.72–377.93, p = 0.019) remained as an independent risk factor for fetal loss. Conclusion We identified immunosuppressive therapy as the major contributing factor for fetal loss in JSLE, reinforcing the importance of contraception. ER -